Hepatitis A vaccines

Vaccines

Volumn , Issue , 2008, Pages 177-203

  Fiore, Anthony E ^a,b   Feinstone, Stephen M ^c   Bell, Beth P ^d  

^a Infectious Diseases Society of America Emerging Infections Network   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 47549084159     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50016-7     Document Type: Chapter

References (435)

1. L Bachman (1952) Infectious hepatitis in Europe. E Rodenwalt (Eds) World Atlas of Epidemic Diseases Hamburg: Falk-Verlag
2. EA Cockayne (1912) Catarrhal jaundice, sporadic and epidemic, and its relations to acute yellow atrophy of the liver. Q J Med 6 1-29.
3. S McDonald (1908) Acute yellow atrophy of the liver. Edinburgh Med J 1 83.
4. W Havens Jr (1946) Immunity in experimentally induced infectious hepatitis. J Exp Med 84 403.
5. JR Neefe, SS Gellis and J Stokes Jr (1946) Homologous serum hepatitis and infectious (epidemic) hepatitis: studies in volunteers bearing on immunological and other characteristics of the etiological agents. Am J Med 1 9.
6. W Havens Jr and J Paul (1997) Prevention of infectious hepatitis with gamma globulin. JAMA 129 270-272.
7. J Stokes Jr, SS Gellis and GM Brother (1945) The use of immune globulin (gamma globulin) in infectious (epidemic) hepatitis in the Mediterranean theatre of operations. JAMA 128 1062.
8. FA MacCallum (1947) Homologous serum hepatitis. Lancet 2 691-692.
9. AJ Zuckerman (1983) The history of viral hepatitis from antiquity to the present. F Deinhardt, J Deinhardt (Eds) Viral Hepatitis: Laboratory and Clinical Science New York: Marcel Dekker 3-32.
10. R Ward, S Krugman and JP Giles (1958) Infectious hepatitis: studies of its natural history and prevention. N Engl J Med 258 407.
11. JL Melnick and JD Boggs (1972) Human volunteer and tissue culture studies of viral hepatitis. Can Med Assoc J 106(Suppl 7),
12. SM Feinstone, AZ Kapikian and RH Purcell (1973) Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 182 1026-1028.
13. BP Bell (2002) Global epidemiology of hepatitis A: implications for control strategies. HS Margolis, MJ Alter, JT Liang, JL Dienstag (Eds) Viral Hepatitis and Liver Disease London: International Medical Press 9-14.
14. KH Jacobsen and JS Koopman (2004) Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 132 1005-1022.
15. BP Bell, D Kruszon-Moran, CN Shapiro, et al. (2005) Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine 23 5798-5806.
16. Centers for Disease Control and Prevention (2006) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 55(RR-7), 1-24.
17. ML Halliday, L-Y Kang, T-K Zhou, et al. (1991) An epidemic of hepatitis A attributable to the ingestion of raw clams in Shanghai, China. J Infect Dis 164 852-859.
18. S Krugman, JP Giles and J Hammond (1967) Infectious hepatitis: evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 200 365-373.
19. HS Margolis and OV Nainan (1990) Identification of virus components in circulating immune complexes isolated during hepatitis A virus infection. Hepatology 11 31-37.
20. RJ Sherertz, BA Russell and PD Reuman (1984) Transmission of hepatitis A by transfusion of blood products. Arch Intern Med 144 1579-1580.
21. RH Purcell, DC Wong and M Shapiro (2002) Relative infectivity of hepatitis A virus by the oral and intravenous routes in 2 species of nonhuman primates. J Infect Dis 185 1668-1771.
22. P Skinhoj, C Gluud and K Ramsoe (1981) Traveler's hepatitis: origin and characteristics of cases in Copenhagen 1976–1978. Scand J Infect Dis 13 1-4.
23. GA Gingrich, SC Hadler, HA Elder, et al. (1983) Serologic investigation of an outbreak of hepatitis A in a rural day-care center. Am J Public Health 73 1190-1193.
24. SC Hadler, HM Webster, JJ Erben, et al. (1980) Hepatitis A in day-care centers: a community-wide assessment. N Engl J Med 302 1222-1227.
25. WM Lednar, SM Lemon, JW Kirkpatrick, et al. (1985) Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 122 226-233.
26. LN Fishman, MM Jonas and JE Lavine (1996) Update on viral hepatitis in children. Pediatr Clin North Am 43 57-74.
27. SM Lemon (1985) Type A viral hepatitis: new developments in an old disease. N Engl J Med 313 1059-1067.
28. MJ Tong, NS El Farra and MI Grew (1995) Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis 171(Suppl 1), S15-S18.
29. RS Koff (1992) Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 10(Suppl 1), S15-S17.
30. MH Sjogren, H Tanno, O Fay, et al. (1987) Hepatitis A virus in stool during clinical relapse. Ann Intern Med 106 221-226.
31. SC Gordon, KR Reddy, L Schiff, et al. (1984) Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 101 635-637.
32. ER Schiff (1992) Atypical clinical manifestations of hepatitis A. Vaccine 10(Suppl 1), S18-S20.
33. AE Gimson, YS White, AL Eddleston, et al. (1983) Clinical and prognostic differences in fulminant hepatitis type A, B, and non-A, non-B. Gut 24 1194-1198.
34. EF Sagi, N Linder and D Shouval (1985) Papular acrodermatitis of childhood associated with hepatitis A virus infection. Pediatr Dermatol 3 31-33.
35. RD Inman, M Hodge, ME Johnston, et al. (1986) Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection. Ann Intern Med 105 700-703.
36. Y Ilan, M Hillman, R Oren, et al. (1990) Vasculitis and cryoglobulinemia associated with persisting cholestatic hepatitis A virus infection. Am J Gastroenterol 85 586-587.
37. M Dan and R Yaniv (1990) Cholestatic hepatitis, cutaneous vasculitis, and vascular deposits of immunoglobulin M and complement associated with hepatitis A virus infection. Am J Med 89 103-104.
38. IR Willner, MD Uhl, SC Howard, et al. (1998) Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 128 111-114.
39. E Tabor (1987) Guillain-Barré syndrome and other neurologic syndromes in hepatitis A, B, and non-A, non-B. J Med Virol 21 207-216.
40. G Pelletier, D Elghozi, C Trepo, et al. (1985) Mononeuritis in acute viral hepatitis. Digestion 32 53-56.
41. VV Bosch, PC Dowling and SD Cook (1983) Hepatitis A virus immunoglobulin M antibody in acute neurological disease. Ann Neurol 14 685-687.
42. J Azuri, T Lerman-Sagie, A Mizrahi, et al. (1999) Guillain-Barré syndrome following serological evidence of hepatitis A in a child. Eur J Pediatr 158 341-342.
43. A Aydin, S Mikla, C Ficicioglu, et al. (1999) Nephrotic syndrome associated with hepatitis A virus infection. Pediatr Infect Dis J 18 391.
44. G Demircin, A Oner, K Tinaztepe, et al. (1998) Acute glomerulonephritis in hepatitis A virus infection. J Pediatr Gastroenterol Nutr 27 86-89.
45. SM Jamil and SG Massry (1998) Acute anuric renal failure in nonfulminant hepatitis A infection. Am J Nephrol 18 329-332.
46. A Mishra, S Saigal, R Gupta, et al. (1999) Acute pancreatitis associated with viral hepatitis: a report of six cases with review of literature. Am J Gastroenterol 94 2292-2295.
47. MY Maiga, F Oberti, H Rifflet, et al. (1997) Hematologic manifestations related to hepatitis A virus: 3 cases. Gastroenterol Clin Biol 21 327-330.
48. S Vento, T Garofano, G Di Perri, et al. (1991) Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 337 1183-1187.
49. D Ertem, Y Acar, C Arat, et al. (1999) Thrombotic and thrombocytopenic complications secondary to hepatitis A infection in children. Am J Gastroenterol 94 3653-3655.
50. MA Almuneef, ZA Memish, HH Balkhy, et al. (2006) Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology 130 1129-1134.
51. M McNeil, JF Hoy, MJ Richards, et al. (1984) Aetiology of fatal viral hepatitis in Melbourne: a retrospective study. Med J Aust 141 637-640.
52. WGE Cooksley (2000) What did we learn from the Shanghai hepatitis A epidemic. J Viral Hep 7(Suppl1), 1-3.
53. S Vong, AE Fiore, DO Haight, et al. (2005) Vaccination in the county jail as a strategy to reach high risk adults during a community-based hepatitis A outbreak among methamphetamine drug users. Vaccine 23 1021-1028.
54. AS Craig, DC Sockwell, W Schaffner, et al. (1998) Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A. Clin Infect Dis 27 531-535.
55. CDC Hepatitis Surveillance Report No. 60. 2005. Atlanta, Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/hep_surveillance_60.pdf
56. Centers for Disease Control and Prevention (2007) Surveillance for Acute Viral Hepatitis—United States, 2005. MMWR 56(SS-3), 1-24.
57. M Ciocca (2000) Clinical course and consequences of hepatitis A infection. Vaccine 18 S71-S74.
58. R Kumashiro, M Sata and H Suzuki (1988) Clinical study of acute hepatitis type A in patients older than 50 years. Acta Hepatol Jpn 29 457-462.
59. ID Gust and SM Feinstone (1988) History. ID Gust, SM Feinstone (Eds) Hepatitis Boca Raton, FL: CRC Press 1-19.
60. ME Wise and F Sorvillo (2005) Hepatitis A-related mortality in California, 1989–2000: analysis of multiple cause-coded death data. AM J Public Health 95 900-905.
61. EA Akriviadis and AG Redeker (1989) Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med 110 838-839.
62. BP Bell (2000) Hepatitis A and hepatitis B vaccination of patients with chronic liver disease. Acta Gastroenterol Belg 63 359-365.
63. D Datta, I Williams, DH Culver, et al. (2000) Association between deaths due to hepatitis A and chronic liver disease, United States, 1981–1997. Antiviral Ther 5(Suppl 1), 79.
64. EB Keeffe (1995) Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 90 201-205.
65. SM Lemon and CN Shapiro (1994) The value of immunization against hepatitis A. Infect Agents Dis 3 38-49.
66. S Vento, T Garofano, C Renzini, et al. (1998) Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 338 286-290.
67. JL Melnick (1992) Properties and classification of hepatitis A virus. Vaccine 1(10 SupplS), 24-S26.
68. BH Robertson, RW Jansen, B Khanna, et al. (1992) Genetic relatedness of hepatitis A virus strains recovered from different geographical regions. J Gen Virol 73 1365-1377.
69. L Lu, KZ Ching, VS de Paula, T Nakano, et al. (2004) Characterization of the complete genomic sequence of genotype II hepatitis A virus (CF53/Berne isolate). J Gen Virol 85 2943-2952.
70. K Fujiwara, O Yokosuka, F Imazeki, et al. (2003) Analysis of the genotype-determining region of hepatitis A viral RNA in relation to disease severities. Hepatol Res 25 124-134.
71. A Martin and SM Lemon (2006) Hepatitis A virus: from discovery to vaccines. Hepatology 43 S164-S172.
72. G Siegl, GG Frosner, V Gauss-Muller, et al. (1981) The physicochemical properties of infectious hepatitis A virions. J Gen Virol 57 331-341.
73. SM Lemon, RW Jansen and JE Newbold (1985) Infectious hepatitis A virus particles produced in cell culture consist of three distinct types with different buoyant densities in CsCl. J Virol 54 78-85.
74. E Nissen, P Konig, SM Feinstone and G Pauli (1996) Inactivation of hepatitis A and other enteroviruses during heat treatment (pasteurization). Biologicals 24 339-341.
75. P Murphy, T Nowak, SM Lemon and J Hilfenhaus (1993) Inactivation of hepatitis A virus by heat treatment in aqueous solution. J Med Virol 41 61-64.
76. DW Griffin, KA Donaldson, JH Paul and JB Rose (2003) Pathogenic human viruses in coastal waters. Clin Microbiol Rev 16 129-143.
77. J Millard, H Appleton and JV Parry (1987) Studies on heat inactivation of hepatitis A virus with special reference to shellfish. Part 1. Procedures for infection and recovery of virus from laboratory-maintained cockles. Epidemiol Infect 98 397-414.
78. G Siegl, M Weitz and G Kronauer (1984) Stability of hepatitis A virus. Intervirology 22 218-226.
79. DA Peterson, TR Hurley, JC Hoff and LG Wolfe (1983) Effect of chlorine treatment on infectivity of hepatitis A virus. Appl Environ Microbiol 45 223-227.
80. MJ Casteel, K Jayaraj, A Gold, LM Ball and MD Sobsey (2004) Photoinactivation of hepatitis A virus by synthetic porphyrins. Photochem Photobiol 80 294-300.
81. JI Cohen (1989) Hepatitis A virus: insights from molecular biology. Hepatology 9 889-895.
82. M Weitz, BM Baroudy, WL Maloy, et al. (1986) Detection of a genome-linked protein (VPg) of hepatitis A virus and its comparison with other picornaviral VPgs. J Virol 60 124-130.
83. EA Brown, AJ Zajac and SM Lemon (1994) In vitro characterization of an internal ribosomal entry site (IRES) present within the 5’ nontranslated region of hepatitis A virus RNA: comparison with the IRES of encephalomyocarditis virus. J Virol 68 1066-1074.
84. MJ Glass, XY Jia and DF Summers (1993) Identification of the hepatitis A virus internal ribosome entry site: in vivo and in vitro analysis of bicistronic RNAs containing the HAV 5’ noncoding region. Virology 193 842-852.
85. JI Cohen, JR Ticehurst, RH Purcell, et al. (1987) Complete nucleotide sequence of wild-type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses. J Virol 61 50-59.
86. T Schultheiss, YY Kusov and V Gauss-Muller (1994) Proteinase 3C of hepatitis A virus (HAV) cleaves the HAV polyprotein P2-P3 at all sites including VP1/2A and 2A/2B. Virology 198 275-281.
87. T Schultheiss, W Sommergruber, Y Kusov and V Gauss-Muller (1995) Cleavage specificity of purified recombinant hepatitis A virus 3C proteinase on natural substrates. J Virol 69 1727-1733.
88. XY Jia, DF Summers and E Ehrenfeld (1993) Primary cleavage of the HAV capsid protein precursor in the middle of the proposed 2A coding region. Virology 193 515-519.
89. A Martin, N Escriou, SF Chao, et al. (1995) Identification and site-directed mutagenesis of the primary (2A/2B) cleavage site of the hepatitis A virus polyprotein: functional impact on the infectivity of HAV RNA transcripts. Virology 213 213-222.
90. M Chow, JF Newman, D Filman, et al. (1987) Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature 327 482-486.
91. DC Ansardi, DC Porter and CD Morrow (1992) Myristylation of poliovirus capsid precursor P1 is required for assembly of subviral particles. J Virol 66 4556-4563.
92. M Tesar, XY Jia, DF Summers and E Ehrenfeld (1993) Analysis of a potential myristylation site in hepatitis A virus capsid protein VP4. Virology 194 616-626.
93. SA Harmon, SU Emerson, YK Huang, et al. (1995) Hepatitis A viruses with deletions in the 2A gene are infectious in cultured cells and marmosets. J Virol 69 5576-5581.
94. MR Beard, L Cohen, SM Lemon and A Martin (2001) Characterization of recombinant hepatitis A virus genomes containing exogenous sequences at the 2A/2B junction. J Virol 75 1414-1426.
95. AW Funkhouser, RH Purcell, E D'Hondt and SU Emerson (1994) Attenuated hepatitis A virus: genetic determinants of adaptation to growth in MRC-5 cells. J Virol 68 148-157.
96. SM Lemon, RW Jansen and EA Brown (1992) Genetic, antigenic and biological differences between strains of hepatitis A virus. Vaccine 10(Suppl 1), S40–S44.
97. JW LeDuc, SM Lemon, CM Keenan, et al. (1983) Experimental infection of the New World owl monkey (Aotus trivirgatus) with hepatitis A virus. Infect Immun 40 766-772.
98. BL Innis, R Snitbhan, P Kunasol, et al. (1994) Protection against hepatitis A by an inactivated vaccine. JAMA 271 1328-1334.
99. DR Nalin, BJ Kuter, L Brown, et al. (1993) Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 18(Suppl 2), S51-S55.
100. EA Brown, RW Jansen and SM Lemon (1989) Characterization of a simian hepatitis A virus (HAV): antigenic and genetic comparison with human HAV. J Virol 63 4932-4937.
101. JT Stapleton and SM Lemon (1987) Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus. J Virol 61 491-498.
102. LH Ping, RW Jansen, JT Stapleton, et al. (1988) Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus. Proc Natl Acad Sci U S A 85 8281-8285.
103. D Feigelstock, P Thompson, P Mattoo, et al. (1998) The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor. J Virol 72 6621-6628.
104. E Silberstein, G Dveksler and GG Kaplan (2001) Neutralization of hepatitis A virus (HAV) by an immunoadhesin containing the cysteine-rich region of HAV cellular receptor-1. J Virol 75 717-725.
105. A Dotzauer, U Gebhardt, K Bieback, et al. (2000) Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor. J Virol 74 10950-10957.
106. JJ McIntire, SE Umetsu, C Macaubas, et al. (2003) Immunology: hepatitis A virus link to atopic disease. Nature 425 576.
107. NL Teterina, K Bienz, D Egger, et al. (1997) Induction of intracellular membrane rearrangements by HAV proteins 2C and 2BC. Virology 237 66-677.
108. T Cromeans, MD Sobsey and HA Fields (1987) Development of a plaque assay for a cytopathic, rapidly replicating isolate of hepatitis A virus. J Med Virol 22 45-56.
109. SM Lemon, PC Murphy, PA Shields, et al. (1991) Antigenic and genetic variation in cytopathic hepatitis A virus variants arising during persistent infection: evidence for genetic recombination. J Virol 65 2056-2065.
110. K Brack, W Frings, A Dotzauer and A Vallbracht (1998) A cytopathogenic, apoptosis-inducing variant of hepatitis A virus. J Virol 72 3370-3376.
111. K Konduru and GG Kaplan (2006) Stable growth of wild-type hepatitis A virus in cell culture. J Virol 80 1352-1360.
112. A Dotzauer, SM Feinstone and G Kaplan (1994) Susceptibility of nonprimate cell lines to hepatitis A virus infection. J Virol 68 6064-6068.
113. W Frings and A Dotzauer (2001) Adaptation of primate cell-adapted hepatitis A virus strain HM175 to growth in guinea pig cells is independent of mutations in the 5’ nontranslated region. J Gen Virol 82 597-602.
114. DA Feigelstock, P Thompson and GG Kaplan (2005) Growth of hepatitis A virus in a mouse liver cell line. J Virol 79 2950-2955.
115. PJ Provost, RP Bishop, RJ Gerety, et al. (1986) New findings in live, attenuated hepatitis A vaccine development. J Med Virol 20 165-175.
116. SM Feinstone, RJ Daemer, ID Gust and RH Purcell (1983) Live attenuated vaccine for hepatitis A. Dev Biol Stand 54 429-432.
117. JS Mao (1990) Development of live, attenuated hepatitis A vaccine (H2-strain). Vaccine 8 523-524.
118. JI Cohen, B Rosenblum, SM Feinstone, et al. (1989) Attenuation and cell culture adaptation of hepatitis A virus (HAV): a genetic analysis with HAV cDNA. J Virol 63 5364-5370.
119. MS Balayan (1992) Natural hosts of hepatitis A virus. Vaccine 10(Suppl 1), S27–S31.
120. JE Maynard, D Lorenz, DW Bradley, et al. (1975) Review of infectivity studies in nonhuman primates with virus-like particles associated with MS-1 hepatitis. Am J Med Sci 270 81-85.
121. BH Robertson (2001) Viral hepatitis and primates: historical and molecular analysis of human and nonhuman primate hepatitis A, B, and the GB-related viruses. J Viral Hepat 8 233-242.
122. B Hornei, R Kammerer, P Moubayed, et al. (2001) Experimental hepatitis A virus infection in guinea pigs. J Med Virol 64 402-409.
123. LV Asher, LN Binn, TL Mensing, et al. (1995) Pathogenesis of hepatitis A in orally inoculated owl monkeys (Aotus trivirgatus). J Med Virol 47 260-268.
124. P Karayiannis, T Jowett, M Enticott, et al. (1986) Hepatitis A virus replication in tamarins and host immune response in relation to pathogenesis of liver cell damage. J Med Virol 18 261-276.
125. S Krugman, R Ward and JP Giles (1959) Infectious hepatitis: detection of virus during the incubation period and in clinically inapparent infection. N Engl J Med 261 729-734.
126. H Yotsuyanagi, S Iino, K Koike, et al. (1993) Duration of viremia in human hepatitis A viral infection as determined by polymerase chain reaction. J Med Virol 40 35-38.
127. JI Cohen, S Feinstone and RH Purcell (1989) Hepatitis A virus infection in a chimpanzee: duration of viremia and detection of virus in saliva and throat swabs. J Infect Dis 160 887-890.
128. WA Bower, OV Nainan, X Han, et al. (2000) Duration of viremia in hepatitis A virus infection. J Infect Dis 182 12-17.
129. AN Schulman, JL Dienstag, DR Jackson, et al. (1976) Hepatitis A antigen particles in liver, bile, and stool of chimpanzees. J Infect Dis 134 80-84.
130. KK Krawczynski, DW Bradley, BL Murphy, et al. (1981) Pathogenetic aspects of hepatitis A virus infection in enterally inoculated marmosets. Am J Clin Pathol 76 698-706.
131. DW Bradley, FB Hollinger, CL Hornbeck and JE Maynard (1976) Isolation and characterization of hepatitis A virus. Am J Clin Pathol 65 876-889.
132. A Vallbracht and B Fleischer (1992) Immune pathogenesis of hepatitis A. Arch Virol Suppl 4 3-4.
133. I Kurane, LN Binn, WH Bancroft and FA Ennis (1985) Human lymphocyte responses to hepatitis A virus-infected cells: interferon production and lysis of infected cells. J Immunol 135 2140-2144.
134. GL Davis, JH Hoofnagle and JG Waggoner (1984) Acute type A hepatitis during chronic hepatitis B virus infection: association of depressed hepatitis B virus replication with appearance of endogenous alpha interferon. J Med Virol 14 141-147.
135. R Zachoval, J Abb, V Zachoval, et al. (1986) Circulating interferon in patients with acute hepatitis A. J Infect Dis 153 1174-1175.
136. PL Winokur and JT Stapleton (1992) Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 14 580-586.
137. JT Stapleton (1995) Host immune response to hepatitis A virus. J Infect Dis 171(Suppl 1), S9-S14.
138. JT Stapleton, DK Lange, JW LeDuc, et al. (1991) The role of secretory immunity in hepatitis A virus infection. J Infect Dis 163 7-11.
139. SA Locarnini, AG Coulepis, AM Stratton, et al. (1979) Solid-phase enzyme-linked immunosorbent assay for detection of hepatitis A-specific immunoglobulin M. J Clin Microbiol 9 459-465.
140. BG Hansson, JK Calhoun, DC Wong, et al. (1981) Serodiagnosis of viral hepatitis A by a solid-phase radioimmunoassay specific for IgM antibodies. Scand J Infect Dis 13 5-9.
141. W Duermyer, F Wielaard and J van der Veen (1979) A new principle for the detection of specific IgM antibodies applied in an ELISA for hepatitis A. J Med Virol 4 25-32.
142. HW Kao, M Ashcavai and AG Redeker (1984) The persistence of hepatitis A IgM antibody after acute clinical hepatitis A. Hepatology 4 933-936.
143. LC Castrodale, A Fiore and T Schmidt (2005) Detection of immunoglobulin M antibody to hepatitis A virus in Alaska residents without other evidence of hepatitis. Clin Infect Dis 41 e86-e88.
144. CDC (2005) Positive test results for acute hepatitis A virus infection among persons with no recent history of acute hepatitis—United States, 2002–2004. MMWR 54 453-456.
145. RW Jansen, G Siegl and SM Lemon (1990) Molecular epidemiology of human hepatitis A virus defined by an antigen-capture polymerase chain reaction method. Proc Natl Acad Sci U S A 87 2867-2871.
146. RH Purcell, PM Mannucci, S Gdovin, et al. (1994) Virology of the hepatitis A epidemic in Italy. Vox Sang 67(Suppl 4), 2-7.
147. YJ Hutin, V Pool, EH Cramer, et al. (1999) A multistate, foodborne outbreak of hepatitis A. N Engl J Med 340 595-602.
148. J O'Grady (1992) Management of acute and fulminant hepatitis A. Vaccine 10(Suppl 1), S21-S23.
149. CJ Tibbs and R Williams (1995) Liver transplantation for acute and chronic viral hepatitis. J Viral Hepat 2 65-72.
150. DH Van Thiel (1993) When should a decision to proceed with transplantation actually be made in cases of fulminant or subfulminant hepatic failure: at admission to hospital or when a donor organ is made available? J Hepatol 17 1-2.
151. E Fagan, G Yousef, J Brahm, et al. (1990) Persistence of hepatitis A virus in fulminant hepatitis and after liver transplantation. J Med Virol 30 131-136.
152. P Coursaget, D Leboulleux, Y Gharbi, et al. (1995) Etiology of acute sporadic hepatitis in adults in Senegal and Tunisia. Scand J Infect Dis 27 9-11.
153. E Tsega, B Mengesha, BG Hansson, et al. (1986) Hepatitis A, B, and delta infection in Ethiopia: a serologic survey with demographic data. Am J Epidemiol 123 344-351.
154. Y Batra, B Bhatkal, B Ojha, et al. (2002) Vaccination against hepatitis A virus may not be required for schoolchildren in northern India: results of a seroepidemiological survey. Bull WHO 80 728-731.
155. FJ Bowden, BJ Currie, NC Miller, et al. (1994) Should aboriginals in the ‘top end’ of the Northern Territory be vaccinated against hepatitis A? Med J Aust 161 372-373.
156. J Cianciara (2000) Hepatitis A shifting epidemiology in Poland and Eastern Europe. Vaccine 18(Suppl 1), S68-S70.
157. MS Green, C Block and PE Slater (1989) Rise in the incidence of viral hepatitis in Israel despite improved socioeconomic conditions. Rev Infect Dis 11 464-469.
158. M Gdalevich, I Grotto, Y Mandel, et al. (1998) Hepatitis A antibody prevalence among young adults in Israel-the decline continues. Epidemiol Infect 121 477-479.
159. BL Innis, R Snitbhan, CH Hoke, et al. (1991) The declining transmission of hepatitis A in Thailand. J Infect Dis 163 989-995.
160. P Kunasol, G Cooksley, VF Chan, et al. (1998) Hepatitis A virus: declining seroprevalence in children and adolescents in Southeast Asia. Southeast Asian J Trop Med Public Health 29 255-262.
161. AD Fix, O san Martin, L Gallicchio, et al. (2002) Age-specific prevalence of antibodies to hepatitis A Santiago, Chile: risk factors and shift in age of infection among children and young adults. Am J Trop Med Hyg 66 628-632.
162. JR Pinho, LM Sumita, RC Moreira, et al. (1998) Duality of patterns in hepatitis A epidemiology: a study involving two socioeconomically distinct populations in Campinas, Sao Paulo State, Brazil. Rev Inst Med Trop Sao Paulo 40 105-106.
163. Y Poovorawan, T Vimolkej, V Chongsrisawat, et al. (1997) The declining pattern of seroepidemiology of hepatitis A virus infection among adolescents in Bangkok, Thailand. Southeast Asian J Trop Med Public Health 28 154-157.
164. K Das, A Jain, S Gupta, et al. (2000) The changing epidemiological pattern of hepatitis A in an urban population of India: emergence of a trend similar to the European countries. Eur J Epidemiol 16 507-510.
165. R Tapia-Conyer, JI Santos, AM Cavalcanti, et al. (1999) Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg 61 825-829.
166. H Tufenkeji (2000) Hepatitis A shifting epidemiology in the Middle East and Africa. Vaccine 18(Suppl 1), S65-S67.
167. LY Wang, YW Cheng, SJ Chou, et al. (1993) Secular trend and geographical variation in hepatitis A infection and hepatitis B carrier rate among adolescents in Taiwan: an island-wide survey. J Med Virol 39 1-5.
168. C-H Park, Y-K Cho, J-H Park, et al. (2006) Changes in the age-specific prevalence of hepatitis A virus antibodies: a 10-year cohort study in Jinju. South Korea Clin Infect Dis 42 1148-1150.
169. RG Sacy, M Haddad, G Baasiri, et al. (2005) Hepatitis A in Lebanon: a changing epidemiological pattern. Am J Trop Med Hyg 73 453-456.
170. JC Victor, TY Surdina, SZ Suleimeova, et al. (2005) The increasing prominence of household transmission of hepatitis A in an area undergoing a shift in endemicity. Epidemiol Infect 163 204-210.
171. M Ciocca (2000) Clinical course and consequences of hepatitis A infection. Vaccine 18(Suppl 1), S71-S74.
172. U Shah, Z Habib and RE Kleinman (2000) Liver failure attributable to hepatitis A virus infection in a developing country. Pediatrics 105 436-438.
173. BP Bell, CN Shapiro, MJ Alter, et al. (1998) The diverse patterns of hepatitis A epidemiology in the United States-implications for vaccination strategies. J Infect Dis 178 1579-1584.
174. A Gil, A Gonzalez, R Dal Re, et al. (1998) Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents. J Infect 36 53-56.
175. CN Shapiro, PJ Coleman, GM McQuillan, et al. (1992) Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. Vaccine 10(Suppl 1), S59-S62.
176. WM Prodinger, C Larcher, BM Solder, et al. (1994) Hepatitis A in Western Austria-the epidemiological situation before the introduction of active immunisation. Infection 22 53-55.
177. F Termorshuizen, JW Dorigo-Zetsma, HE de Melker, et al. (2000) The prevalence of antibodies to hepatitis A virus and its determinants in The Netherlands: a population-based survey. Epidemiol Infect 124 459-466.
178. M Bottiger, B Christenson and L Grillner (1997) Hepatitis A immunity in the Swedish population: a study of the prevalence of markers in the Swedish population. Scand J Infect Dis 29 99-102.
179. A Wasley, T Samandari and BP Bell (2005) Incidence of hepatitis A in the United States in the era of vaccination. JAMA 294 194-201.
180. GL Armstrong and BP Bell (2002) Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 109 839-845.
181. Centers for Disease Control and Prevention (1999) Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 48(RR-12), 1-37.
182. CDC (1996) Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 45 1-30.
183. T Samandari, BP Bell and GL Armstrong (2004) Quantifying the impact of hepatitis A immunization in the United States, 1995–2001. Vaccine 22 4342-4350.
184. SM Cotter, S Sansom, B Lee, et al. (2003) Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination. J Infect Dis 187 1235-1240.
185. MS Friedman, PA Blake, JE Koehler, et al. (2000) Factors influencing a communitywide campaign to administer hepatitis A vaccine to men who have sex with men. Am J Public Health 90 1942-1946.
186. J Harkess, B Gildon and GR Istre (1989) Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984–87. Am J Public Health 79 463-466.
187. YJ Hutin, BP Bell, KL Marshall, et al. (1999) Identifying target groups for a potential vaccination program during a hepatitis A communitywide outbreak. Am J Public Health 89 918-921.
188. FE Shaw Jr, JH Sudman, SM Smith, et al. (1986) A community-wide epidemic of hepatitis A in Ohio. Am J Epidemiol 123 1057-1065.
189. AS Craig, DC Sockwell, W Schaffner, et al. (1998) Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A. Clin Infect Dis 27 531-535.
190. F Averhoff, CN Shapiro, BP Bell, et al. (2001) Control of hepatitis A through routine vaccination of children. JAMA 286 2968-2973.
191. CJ Staes, TL Schlenker, I Risk, et al. (2000) Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics 106 E54.
192. BH Robertson, F Averhoff, TL Cromeans, et al. (2000) Genetic relatedness of hepatitis A virus isolates during a community-wide outbreak. J Med Virol 62 144-150.
193. KM Thorburn, R Bohorques, P Stepak, et al. (2001) Immunization strategis to control a community-wide hepatitis A epidemic. Epidemiol Infect 127 461-467.
194. LV Venczel, MM Desai, PD Vertz, et al. (2001) The role of child care in a community-wide outbreak of hepatitis A. Pediatrics 108 E78.
195. CN Shapiro and SC Hadler (1991) Hepatitis A and hepatitis B virus infections in day-care settings. Pediatr Ann 20 435-441.
196. LA Jackson, LK Stewart, SL Solomon, et al. (1996) Risk of infection with hepatitis A, B or C, cytomegalovirus, varicella or measles among child care providers. Pediatr Infect Dis J 15 584-589.
197. W Szmuness, RH Purcell, JL Dienstag, et al. (1977) Antibody to hepatitis A antigen in institutionalized mentally retarded patients. JAMA 237 1702-1705.
198. DD Shaw, DC Whiteman, AD Merritt, et al. (1999) Hepatitis A outbreaks among illicit drug users and their contacts in Queensland, 1997. Med J Aust 170 584-587.
199. D O'Donovan, RP Cooke, R Joce, et al. (2001) An outbreak of hepatitis A amongst injecting drug users. Epidemiol Infect 127 469-473.
200. YJ Hutin, KM Sabin, LC Hutwagner, et al. (2000) Multiple modes of hepatitis A virus transmission among methamphetamine users. Am J Epidemiol 152 186-192.
201. K Ivie, C Spruill and BP Bell (2000) Prevalence of hepatitis A virus infection among illicit drug users, 1993–1994. Antiviral Ther 5(Suppl 1), A.7.
202. SA Villano, KE Nelson, D Vlahov, et al. (1997) Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin Infect Dis 25 726-728.
203. ML Stokes, MJ Ferson and LC Young (1997) Outbreak of hepatitis A among homosexual men in Sydney. Am J Public Health 87 2039-2041.
204. KJ Henning, E Bell, J Braun, et al. (1995) A community-wide outbreak of hepatitis A: risk factors for infection among homosexual and bisexual men. Am J Med 99 132-136.
205. Centers for Disease Control (1992) Hepatitis A among homosexual men: United States, Canada, and Australia. MMWR 41 161-164.
206. MH Katz, L Hsu, E Wong, et al. (1997) Seroprevalence of and risk factors for hepatitis A infection among young homosexual and bisexual men. J Infect Dis 175 1225-1229.
207. MW Mah, RA Royce, PJ Rathouz, et al. (1994) Prevalence of hepatitis A antibodies in hemophiliacs: preliminary results from the Southeastern Delta Hepatitis Study. Vox Sang 67(Suppl 1), 21-22.
208. JM Soucie, BH Robertson, BP Bell, et al. (1998) Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 38 573-579.
209. PM Mannucci, E Santagostino, E Di Bona, et al. (1994) The outbreak of hepatitis A in Italian patients with hemophilia: facts and fancies. Vox Sang 67(Suppl 1), 31-35.
210. CDC Blood safety monitoring among persons with bleeding disorders-United States, May 1998-June 2002. MMWR 51 1152-1154.
211. LS Rosenblum, ME Villarino, OV Nainan, et al. (1991) Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis 164 476-482.
212. BS Klein, JA Michaels, MW Rytel, et al. (1984) Nosocomial hepatitis A: a multinursery outbreak in Wisconsin. JAMA 252 2716-2721.
213. IB Weisfuse, DJ Graham, M Will, et al. (1990) An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cells. J Infect Dis 161 647-652.
214. RA Goodman (1985) Nosocomial hepatitis A. Ann Intern Med 103 452-454.
215. P Skinhoj, LR Mathiesen and P Kryger (1987) Fecal excretion of hepatitis A virus in patients with symptomatic hepatitis A infection. Ann Intern Med 106 221-226.
216. GJ Papaevangelou, AJ Roumeliotou-Karayannis and PC Contoyannis (1981) The risk of nosocomial hepatitis A and B virus infections from patients under care without isolation precaution. J Med Virol 7 143-148.
217. A Gibas, DR Blewett, DA Schoenfeld, et al. (1992) Prevalence and incidence of viral hepatitis in health workers in the prehepatitis B vaccination era. Am J Epidemiol 136 603-610.
218. R Steffen, M Rickenbach, U Wilhelm, et al. (1987) Health problems after travel to developing countries. J Infect Dis 156 84-91.
219. R Steffen (1992) Risk of hepatitis A in travellers. Vaccine 10(Suppl 1), S69-S72.
220. A Mele, L Sagliocca, F Palumbo, et al. (1991) Travel-associated hepatitis A: effect of place of residence and country visited. J Public Health Med 13 256-259.
221. R Steffen, MA Kane, CN Shapiro, et al. (1994) Epidemiology and prevention of hepatitis A in travelers. JAMA 272 885-889.
222. R Steffen (1995) Hepatitis A in travelers: the European experience. J Infect Dis 171(Suppl 1), S24-S28.
223. M Mutsch, VM Spicher, C Gut and R Steffen (2006) Hepatitis A virus infections in travelers, 1988–2004. Clin Infect Dis 42 490-497.
224. WR Lange and JD Frame (1990) High incidence of viral hepatitis among American missionaries in Africa. Am J Trop Med Hyg 43 527-533.
225. M Weinberg, J Hopkins, L Farrington, L Gresham, M Ginsberg and BP Bell (2004) Hepatitis A in Hispanic children who live along the United States-Mexico border: the role of international travel and food-borne exposures. Pediatrics 114 68-73.
226. B Christenson (1985) Epidemiological aspects of acute viral hepatitis A in Swedish travellers to endemic areas. Scand J Infect Dis 17 5-10.
227. AE Fiore (2004) Hepatitis A transmitted by food. Clin Infect Dis 38 705-715.
228. MS Massoudi, BP Bell, V Paredes, et al. (1999) An outbreak of hepatitis A associated with an infected foodhandler. Public Health Rep 114 157-164.
229. Centers for Disease Control and Prevention (2003) Foodborne transmission of hepatitis A—Massachusetts, 2001. MMWR 52 565-567.
230. CB Dalton, A Haddix, RE Hoffman, et al. (1996) The cost of a food-borne outbreak of hepatitis A in Denver, Colo. Arch Intern Med 156 1013-1016.
231. RH Latham and CA Schable (1982) Foodborne hepatitis A at a family reunion use of IgM-specific hepatitis a serologic testing. Am J Epidemiol 115 640-645.
232. B Mishu, SC Hadler, VA Boaz, et al. (1990) Foodborne hepatitis A: evidence that microwaving reduces risk? J Infect Dis 162 655-658.
233. WE Parkin, P Marzinsky and MR Griffin (1983) Foodborne hepatitis A associated with cheeseburgers. J Med Soc N J 80 612-615.
234. AC Weltman, NM Bennett, DA Ackman, et al. (1996) An outbreak of hepatitis A associated with a bakery, New York, 1994: the 1968 ‘West Branch, Michigan’ outbreak repeated. Epidemiol Infect 117 333-341.
235. CM Dentinger, WA Bower, OV Nainan, et al. (2001) An outbreak of hepatitis A associated with green onions. J Infect Dis 183 1273-1276.
236. LS Rosenblum, IR Mirkin, DT Allen, et al. (1990) A multifocal outbreak of hepatitis A traced to commercially distributed lettuce. Am J Public Health 80 1075-1079.
237. MT Niu, LB Polish, BH Robertson, et al. (1992) Multistate outbreak of hepatitis A associated with frozen strawberries. J Infect Dis 166 518-524.
238. TM Reid and HG Robinson (1987) Frozen raspberries and hepatitis A. Epidemiol Infect 98 109-112.
239. C Wheeler, T Vogt, GL Armstrong, et al. (2005) A foodborne outbreak of hepatitis A in Pennsylvania associated with green onions. N Engl J Med 353 890-897.
240. JJ Amon, R Devasia, G Xia, et al. (2005) Molecular epidemiology of foodborne hepatitis A outbreaks in the United States, 2003. J Infect Dis 192 1323-1330.
241. JC Desenclos, KC Klontz, MH Wilder, et al. (1991) A multistate outbreak of hepatitis A caused by the consumption of raw oysters. Am J Public Health 81 1268-1272.
242. S Bialek, P George, G Xia, et al. (2007) Use of molecular epidemiology to confirm a multistate outbreak of hepatitis A caused by consumption of oysters. J Infect Dis 44 838-840.
243. AB Bloch, SL Stramer, JD Smith, et al. (1990) Recovery of hepatitis A virus from a water Supply responsible for a common source outbreak of hepatitis A. Am J Public Health 80 428-430.
244. G De Serres, TL Cromeans, B Levesque, et al. (1999) Molecular confirmation of hepatitis A virus from well water: epidemiology and public health implications. J Infect Dis 179 37-43.
245. GH Bergeisen, MW Hinds and JW Skaggs (1985) A waterborne outbreak of hepatitis A in Meade County, Kentucky. Am J Public Health 75 161-164.
246. Y Lerman, G Chodik, H Aloni, et al. (1999) Occupations at increased risk of hepatitis A: a 2-year nationwide historical prospective cohort. Am J Epidemiol 150 312-320.
247. C Glas, P Hotz and R Steffen (2001) Hepatitis A in workers exposed to sewage: a systematic review. Occup Environ Med 58 762-768.
248. CJ Poole and AT Shakespeare (1993) Should sewage workers and carers for people with learning disabilities be vaccinated against hepatitis A. BMJ 306 1102.
249. D Trout, C Mueller, L Venczel, et al. (2000) Evaluation of occupational transmission of hepatitis A virus among wastewater workers. J Occup Environ Med 42 83-87.
250. M Weldon, MJ VanEgdom, KA Hendricks, et al. (2000) Prevalence of antibody to hepatitis A virus in drinking water workers and wastewater workers in Texas from 1996 to 1997. J Occup Environ Med 42 821-826.
251. L Venczel, S Brown, H Frumkin, et al. (2003) Prevalence of hepatitis A virus infection among sewage workers in Georgia. Am J Ind Med 43 172-178.
252. NC Tassopoulos, GJ Papaevangelou, JR Ticehurst, et al. (1986) Fecal excretion of Greek strains of hepatitis A virus in patients with hepatitis A and in experimentally infected chimpanzees. J Infect Dis 154 231-237.
253. S Krugman, R Ward and WP Giles (1962) The natural history of infectious hepatitis. Am J Med 32 717-728.
254. SM Lemon (1994) The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products. Vox Sang 67(Suppl 4), 19-23.
255. PF Smith, JC Grabau, A Werzberger, et al. (1997) The role of young children in a community-wide outbreak of hepatitis A. Epidemiol Infect 118 243-252.
256. JC Victor, TY Surdina, SZ Suleimenova, et al. (2006) Person-to-person transmission of hepatitis A virus in an urban area of intermediate endemicity: implications for vaccination strategies. Am J Epidemiol 163 204-210.
257. KA McCaustland, WW Bond, DW Bradley, et al. (1982) Survival of hepatitis A virus in feces after drying and storage for 1 month. J Clin Microbiol 16 957-958.
258. A Mele, T Stroffolini, F Palumbo, et al. (1997) Incidence and risk factors for hepatitis A in Italy: public health indications from a 10-year surveillance. J Hepatol 26 743-747.
259. FB Hollinger, NC Khan, PE Oefinger, et al. (1983) Posttransfusion hepatitis type A. JAMA 250 2313-2317.
260. PM Mannucci, S Gdovin, A Gringeri, et al. (1994) Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 120 1-7.
261. YM Jee, U Go, D Cheon, et al. (2006) Detection of hepatitis A virus from clotting factors implicated as a source of HAV infection among haemophilia patients in Korea. Epidemiol Infect 134 87-93.
262. E Leikin, A Lysikiewicz, D Garry, et al. (1996) Intrauterine transmission of hepatitis A virus. Obstet Gynecol 88 690-691.
263. RS McDuffie Jr and T Bader (1999) Fetal meconium peritonitis after maternal hepatitis A. Am J Obstet Gynecol 180 1031-1032.
264. MJ Tong, M Thursby, J Rakela, et al. (1981) Studies on the maternal-infant transmission of the viruses which cause acute hepatitis. Gastroenterology 80 999-1004.
265. JC Watson, DW Fleming, AJ Borella, et al. (1993) Vertical transmission of hepatitis A resulting in an outbreak in a neonatal intensive care unit. J Infect Dis 167 567-571.
266. JJ Berge, DD Drennan, RJ Jacobs, et al. (2000) The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 31 469-473.
267. SC Hadler, JJ Erben, D Matthews, et al. (1983) Effect of immunoglobulin on hepatitis A in day-care centers. JAMA 249 48-53.
268. O Weiland, B Niklasson, R Berg, et al. (1981) Clinical and subclinical hepatitis A occurring after immunoglobulin prophylaxis among Swedish UN soldiers in Sinai. Scand J Gastroenterol 16 967-972.
269. PF Pierce, M Cappello and KW Bernard (1990) Subclinical infection with hepatitis A in Peace Corps volunteers following immune globulin prophylaxis. Am J Trop Med Hyg 42 465-469.
270. I Kluge (1963) Gamma-globulin in the prevention of viral hepatitis: a study of the effect of medium-size doses. Acta Med Scand 174 469-477.
271. JW Mosley, DM Reisler, D Brachott, et al. (1968) Comparison of two lots of immune serum globulin for prophylaxis of infectious hepatitis. Am J Epidemiol 87 539-550.
272. J Stokes and JR Neefe (1945) The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 127 144-145.
273. N Stokes (1945) The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 127 144-145.
274. RD Aach, WR Elsea, J Lyerly and DA Henderson (1963) Efficacy of varied doses of gamma globulin during an epidemic of infectious hepatitis, Hoonah, Alaska, 1961. Am J Pub Heath 53 1623-1629.
275. EW Fowinkle and N Guthrie (1964) Comparison of two doses of gamma globulin in the prevention of infectious hepatitis. Public Health Rep 79 634-637.
276. E Cohn, J Oncley and LE Strong (1944) Chemical, clinical, and immunological studies on the products of human plasma fractionation: the characterization of the protein fractions of human plasma. J Clin Invest 23 417-432.
277. R Novack, I Williams and B Bell (2007) Update. Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 56 1080-1084.
278. Y Lerman, T Shohat, S Ashkenazi, et al. (1993) Efficacy of different doses of immune serum globulin in the prevention of hepatitis A: a three-year prospective study. Clin Infect Dis 17 411-414.
279. EF Ellis and CS Henney (1969) Adverse reactions following administration of human gamma globulin. J Allergy 43 45-54.
280. J Peetermans (1992) Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine 10(Suppl 1), S99-S101.
281. ME Armstrong, PA Giesa, JP Davide, et al. (1993) Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F. J Hepatol 18(Suppl 2), S20-S26.
282. RA Karron, R Daemer, J Ticehurst, et al. (1988) Studies of prototype live hepatitis A virus vaccines in primate models. J Infect Dis 157 338-345.
283. MH Sjogren, RH Purcell, K McKee, et al. (1992) Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate. Vaccine 10(Suppl 1), S135-S137.
284. K Midthun, E Ellerbeck, K Gershman, et al. (1991) Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis 163 735-739.
285. MW Cho and E Ehrenfeld (1991) Rapid completion of the replication cycle of hepatitis A virus subsequent to reversal of guanidine inhibition. Virology 180 770-780.
286. JI Cohen, JR Ticehurst, SM Feinstone, et al. (1987) Hepatitis A virus cDNA and its RNA transcripts are infectious in cell culture. J Virol 61 3035-3039.
287. SU Emerson, YK Huang, C McRill, et al. (1992) Molecular basis of virulence and growth of hepatitis A virus in cell culture. Vaccine 10(Suppl 1), S36-S39.
288. SU Emerson, YK Huang and RH Purcell (1993) 2B and 2C mutations are essential but mutations throughout the genome of HAV contribute to adaptation to cell culture. Virology 194 475-480.
289. JS Mao, DX Dong, HY Zhang, et al. (1989) Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans. J Infect Dis 159 621-624.
290. FC Zhuang, W Qian, ZA Mao, et al. (2005) Persistent efficacy of live attenuated hepatitis A vaccine (H2 strain) after a mass vaccination program. Chin Med J 118 1851-1856.
291. E Vidor, B Fritzell and S Plotkin (1996) Clinical development of a new inactivated hepatitis A vaccine. Infection 24 447-458.
292. R Gluck, R Mischler, S Brantschen, et al. (1992) Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 90 2491-2495.
293. ID Gust, NI Lehmann, S Crowe, et al. (1985) The origin of the HM175 strain of hepatitis A virus. J Infect Dis 151 365-367.
294. B Flehmig, A Vallbracht and G Wurster (1981) Hepatitis A virus in cell culture. III. Propagation of hepatitis A virus in human embryo kidney cells and human embryo fibroblast strains. Med Microbiol Immunol (Berl) 170 83-89.
295. U Heinricy, YD Stierhof, M Pfisterer, et al. (1987) Properties of a hepatitis A virus candidate vaccine strain. J Gen Virol 68(pt 9), 2487-2493.
296. B Flehmig, U Heinricy and M Pfisterer (1990) Prospects for a hepatitis A virus vaccine. Prog Med Virol 37 56-71.
297. B Flehmig, RF Mauler, G Noll, et al. (1988) Progress in the development of an attenuated, live hepatitis A vaccine. AJ Zuckerman (Eds) Viral Hepatitis and Liver Disease New York: Alan R. Liss 87-90.
298. F Ambrosch, G Wiedermann, S Jonas, et al. (1997) Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15 1209-1213.
299. R Dagan, D Greenberg, P Goldenbertg-Gehtman, et al. (1999) Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine. Vaccine 17 1919-1925.
300. EL López, M Del Carmen Xifró, LE Torrado, et al. (2001) Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J 20 48-52.
301. Centers for Disease Control and Prevention (2001) Notice to readers: FDA approval for a combined hepatitis A and B vaccine. MMWR 50 806-807.
302. F Diaz-Mitoma, B Law and J Parsons (1999) A combined vaccine against hepatitis A and B in children and adolescents. Pediatr Infect Dis J 18 109-114.
303. Product Information Avaxim® Sanofi Pasteur, 2006.
304. Product Information Epaxal® Berna Biotech AG, 2006.
305. TWINRIX Hepatitis A Inactivated and Hepatitis B (Recombinant) Vaccine. Philadelphia, GlaxoSmithKline, 2006.
306. PA Czeschinski, N Binding and U Witting (2000) Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. Vaccine 18 1074-1080.
307. K Van Herck, P van Damme, F Collard, et al. (1999) Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11–18 years. Scand J Gastroenterol 12 1236-1240.
308. J Beran, M Beutels, K Levie, et al. (2000) Vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. J Travel Med 7 246-252.
309. D Overbosch, F Peyron, N Picot, et al. (2005) Combined typhoid fever and hepatitis A vaccine: Comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. J Travel Med 12 319-326. 2005
310. Product Information Hepatyrix. Philadelphia, GlaxoSmithKline, 2006.
311. Product Information Havrix® Hepatitis A Vaccine, Inactivated. Philadelphia, GlaxoSmithKline, 2002.
312. Product Information VAQTA® Hepatitis A Vaccine, Inactivated West Point, PA: Merck & Co., Inc
313. G Wiedermann and F Ambrosch (1994) Immunogenicity of an inactivated hepatitis A vaccine after exposure at 37 degrees C for 1 week. Vaccine 12 401-402.
314. D Shouval, Y Ashur, R Adler, et al. (1993) Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. Vaccine 11(Suppl 1), S9-S14.
315. P van Damme, C Mathei, S Thoelen, et al. (1994) Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 44 435-441.
316. CH Hoke Jr, LN Binn, JE Egan, et al. (1992) Hepatitis A in the US Army: epidemiology and vaccine development. Vaccine 10(Suppl 1), S75-S79.
317. S Fujiyama, K Odoh, I Kuramoto, et al. (1994) Current seroepidemiological status of hepatitis A with a comparison of antibody titers after infection and vaccination. J Hepatol 21 641-645.
318. BP Bell, S Negus, A Fiore, et al. (2007) Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J 26 116-122.
319. R Clemens, A Safary, A Hepburn, et al. (1995) Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 171(Suppl 1), S44-S49.
320. KB Balcarek, MR Bagley, RF Pass, et al. (1995) Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 171(Suppl 1), S70-S72.
321. YC Horng, MH Chang, CY Lee, et al. (1993) Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J 12 359-362.
322. BJ McMahon, J Williams, L Bulkow, et al. (1995) Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. J Infect Dis 171 676-679.
323. L Loutan, P Bouvier, B Althaus and R Glück (1994) Inactivated virosome hepatitis A vaccine. Lancet 343 322-324.
324. BR Holzer, C Hatz, D Schmidt-Sissolak, R Glück, B Althaus and M Egger (1996) Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 14 982-986.
325. SM Lemon and LN Binn (1983) Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 148 1033-1039.
326. R Dagan, J Amir, A Mijalovsky, et al. (2000) Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 19 1045-1052.
327. D Shouval, Y Ashur, R Adler, et al. (1993) Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin. J Hepatol 18(Suppl 2), S32-S37.
328. SM Lemon, PC Murphy, PJ Provost, et al. (1997) Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin. J Infect Dis 176 9-19.
329. MS Green, D Cohen, Y Lerman, et al. (1993) Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin. J Infect Dis 168 740-743.
330. RH Purcell, E D'Hondt, R Bradbury, et al. (1992) Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine 10(Suppl 1), S148-S151.
331. M Piazza, A Safary, A Vegnente, et al. (1999) Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine 17 585-588.
332. GW Letson, CN Shapiro, D Kuehn, et al. (2004) Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 144 327-332.
333. CL Troisi, FB Hollinger, DS Krause, et al. (1997) Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): a comparative study of two dosing schedules. Vaccine 15 1613-1617.
334. V Usonis, V Bakasenas, R Valentelis, et al. (2003) Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine 21 4588-4592.
335. R Lagos, A Munoz, R Dumas, et al. (2003) Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in the presence of maternal antibodies. Vaccine 21 3730-3733.
336. JM Lieberman, M Marcy, S Partridge and JI Ward (1998) Evaluation of hepatitis A vaccine in infants: effect of maternal antibodies on the antibody response [abstr 76]. Abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America, Denver Alexandria, VA: Infectious Diseases Society of America 38.
337. G Kanra, SS Yalçin, A Kara, et al. (2002) Hepatitis A booster vaccine in children after infant immunization. Pediatr Inf Dis J 21 727-730.
338. A Fiore, CN Shapiro, KM Sabin, et al. (2003) Persistence of protective antibody concentrations and response to a booster dose among children given hepatitis A vaccine during infancy: effect of maternal antibody status. Ped Infect Dis J 22 354-359.
339. C Franzen and G Frosner (1981) Placental transfer of hepatitis A antibody. N Engl J Med 304 427.
340. N Linder, Y Karetnyi, Y Gidony, et al. (1999) Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants. Infection 27 128-131.
341. JM Lieberman, S Chang, S Partridge, et al. (2002) Kinetics of maternal hepatitis A antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J 21 347-348.
342. GA Neilsen, NJ Bodsworth and N Watts (1997) Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis 176 1064-1067.
343. G Hess, R Clemens, U Bienzle, et al. (1995) Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 46 40-42.
344. CA Kemper, R Haubrich, I Frank, et al. (2003) Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 187 1327-1331.
345. MR Wallace, CJ Brandt, KC Earhart, et al. (2004) Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 39 1207-1213.
346. D Rimland and JL Guest (2005) Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS 19 1702-1704.
347. AFTB Gouvea, MI De Moraes-Pinto, E Ono, et al. (2005) Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children. Clin Infect Dis 41 544-548.
348. A Weinberg, P Gona, SA Nachman, et al. (2006) Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 193 302-311.
349. EB Keeffe, S Iwarson and BJ McMahon (1998) Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27 881-886.
350. S-D Lee, CY Chan and MY Yu (1997) Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J Med Virol 52 215-218.
351. K Stark, M Günther, R Neuhaus, et al. (1999) Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis 180 2014-2017.
352. JA Dumot, DS Barnes, Z Younossi, et al. (1999) Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 94 1601-1604.
353. M Arslan, RH Wiesner, JJ Poterucha and NN Zein (2001) Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 72 272-276.
354. M Gunther, K Stark, R Neuhaus, et al. (2001) Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 71 477-479.
355. H Briem and A Safary (1994) Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. J Med Virol 44 443-445.
356. PD Reuman, P Kubilis, W Hurni, et al. (1997) The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 15 1157-1161.
357. A Werzberger, B Mensch, B Kuter, et al. (1992) A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327 453-457.
358. OM Perez, C Herzog, M Zellmeyer, et al. (2003) Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: Randomized placebo-controlled trial. J Infect Dis 188 671-677.
359. FE Shaw Jr, CN Shapiro, TK Welty, et al. (1990) Hepatitis transmission among the Sioux Indians of South Dakota. Am J Public Health 80 1091-1094.
360. CM Dentinger, NL Heinrich, BP Bell, et al. (2001) A prevalence study of hepatitis A virus infection in a migrant community: is hepatitis A vaccine indicated? J Pediatr 138 705-709.
361. D Peach, BJ McMahon, L Bulkow, et al. (2002) Impact of recurrent epidemics of hepatitis A virus infection on population immunity levels: Bristol Bay, Alaska. J Infect DIs 186 1081-1085.
362. V Prikazsky, V Olear, A Cernoch, A Safary and FE Andre (1994) Interuption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 44 457-459.
363. C Zamir, S Rishpon, D Zamir, et al. (2001) Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis a vaccine. Eur J Clin Microbiol Infect Dis 20 185-187.
364. SR Bialek, DA Thoroughman, D Hu, et al. (2004) Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska Natives, 1990–2001. Am J Public Health 94 996-1001.
365. Centers for Disease Control and Prevention (1997) Hepatitis A vaccination programs in communities with high rates of hepatitis A. MMWR 46 600-603.
366. BJ McMahon, M Beller, J Williams, et al. (1996) A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 150 733-739.
367. A Werzberger, B Mensch, DR Nalin, et al. (2002) Effectiveness of hepatitis A in a former frequently affected community: 9 years’ follow up after the Monroe field trial of VAQTA®. Vaccine 20 1699-1702.
368. R Dagan, A Leventhal, E Anis, et al. (2005) Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 294 202-210.
369. A Dominguez, L Salleras, G Carmona and J Batalla (2003) Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine 21 698-701.
370. K van Herck, P van Damme, I Dieussaert and M Stoffel (2004) Antibody persistence 10 years after immunization with a two-dose inactivated hepatitis A vaccine [Abstract]. Int J Infect Dis 8(Suppl 1), S225.
371. K van Herck, P van Damme, M Lievens and M Stoffel (2004) Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 72 194-196.
372. PC Fan, MH Chang, PI Lee, et al. (1998) Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine 16 232-235.
373. P van Damme, J Banatvala, O Fay, et al. (2003) Hepatitis A booster vaccination: is there a need? Lancet 362 1065-1071.
374. A Werzberger, B Kuter and D Nalin (1998) Six years’ follow-up after hepatitis A vaccination [letter]. N Engl J Med 338 1160.
375. G Wiedermann, M Kundi and F Ambrosch (1998) Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0–6 schedule). Acta Trop 69 121-125.
376. PA Bovier, J Bock, L Loutan, et al. (2002) Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 68 489-493.
377. JB Cederna, D Klinzman and JT Stapleton (2000) Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine 18 892-898.
378. P Schmidtke, P Habermehl, M Knuf, et al. (2005) Cell mediated and antibody response to inactivated hepatitis A vaccine. Vaccine 23 5127-5132.
379. BH Robertson, EH D'Hondt, J Spelbring, et al. (1994) Effect of postexposure vaccination in a chimpanzee model of hepatitis A virus infection. J Med Virol 43 249-251.
380. L Sagliocca, P Amoroso, T Stroffolini, et al. (1999) Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet 353 1136-1139.
381. BP Bell and HS Margolis (1999) Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection [letter]. Lancet 354 341.
382. JC Victor, AS Monto, TY Surdina, et al. (2007) The relative efficacy of hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 357 1985-1994.
383. American Academy of Pediatrics (2003) Hepatitis A. LK Pickering (Eds) Red Book: Report of the Committee on Infectious Diseases 26th edn. Elk Grove Village, IL: American Academy of Pediatrics 309-318.
384. FE Andre, E D'Hondt, A Delem, et al. (1992) Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 10(Suppl 1), S160-S168.
385. S Black, H Shinefield, J Hansen, E Lewis, L Su and P Coplan (2004) A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults. Vaccine 22 766-772.
386. MT Niu, M Salive, C Krueger, et al. (1998) Two-year review of hepatitis A vaccine safety: data from the Vaccine Adverse Event Reporting System (VAERS). Clin Infect Dis 26 1475-1476.
387. K Stark, M Günther, R Newhaus, et al. (1999) Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis 180 2014-2017.
388. JP Bryan, CH Henry, AG Hoffman, et al. (2000) Randomized, cross-over controlled comparison of two inactivated hepatitis A vaccines. Vaccine 19 743-750.
389. BA Connor, J Phair, D Sack, et al. (2001) Randomized double-blind study in healthy adults to assess the boosting effect of VAQTA or HAVRIX after a single dose of HAVRIX. Clin Infect Dis 34 396-401.
390. BR Beck, CF Hatz, L Loutan and R Steffen (2004) Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine. J Travel Med 11 201-206.
391. JN Zuckerman, CT Kirkpatrick and M Huang (1998) Immunogenicity and reactogenicity of Avaxim (160AU) as compared with Havrix (1440EL.U) as a booster following primary immunization with Havrix (1440EL.U) against hepatitis A. J Travel Med 5 18-22.
392. P Clarke, N Kitchin and F Souverbie (2001) A randomized comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim. Vaccine 19 4429-4433.
393. JL Williams, DA Bruden, HH Cagle, et al. (2003) Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 21 3208-3211.
394. S Iwarson, M Lindh and L Widerstrom (2004) Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J Travel Med 11 120-121.
395. BR Beck, C Hatz, R Bronnimann and C Herzog (2003) Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine. Clin Infect Dis 37 e126-e128.
396. A Zanetti, F Pregliasco, A Andreassi, et al. (1997) Does immunoglobulin interfere with the immunogenicity to Pasteur Merieux inactivated hepatitis A vaccine? J Hepatol 26 25-30.
397. G Wagner, D Lavanchy, R Darioli, et al. (1993) Simultaneous active and passive immunization against hepatitis A studied in a population of travellers. Vaccine 11 1027-1032.
398. A Leentvaar-Kuijpers, RA Coutinho, V Brulein, et al. (1992) Simultaneous passive and active immunization against hepatitis A. Vaccine 10(Suppl 1), S138-S141.
399. EB Walter, RB Hornick and GA Poland (1999) Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. Vaccine 17 1468-1473.
400. F Ambrosch, FE Andre, A Delem, et al. (1992) Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine 10(Suppl 1), S142-S145.
401. A Gil, A Gonzalez, R Dal Re, et al. (1996) Interference assessment of yellow fever vaccine with the immune response to a single-dose inactivated hepatitis A vaccine (1440EL.U.): a controlled study in adults. Vaccine 14 1028-1030.
402. U Bienzle, HL Bock, JP Kruppenbacher, et al. (1996) Immunogenicity of an inactivated hepatitis A vaccine administered according to two different schedules and the interference of other ‘travellers’ vaccines with the immune response. Vaccine 14 501-505.
403. EC Jong, KM Kaplan, KA Eves, et al. (2002) An open randomized study of inactivated hepatitis A vaccine administered concurrently with typhoid fever and yellow fever vaccines. J Travel Med 9 66-70.
404. PA Bovier, B Althaus, R Glueck, et al. (1999) Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J Travel Med 6 228-233.
405. V Usonis, S Meriste, V Bakasenas, et al. (2005) Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12–18 months. Vaccine 23 2602-2606.
406. T Nolan, H Bernstein, MM Blatter, et al. (2006) Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. Pediatrics 118 e602-e609.
407. JP Bryan and M Nelson (1994) Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines. Arch Intern Med 154 663-668.
408. P Bonanni, R Colombai, G Franchi, et al. (1998) Experience of hepatitis A vaccination during an outbreak in a nursery school of Tuscany, Italy. Epidemiol Infect 121 377-380.
409. Y Poovorawan, A Theamboonlers, V Chongsrisawat, et al. (2005) Clinical features and molecular characterization of hepatitis A virus outbreak in a child care center in Thailand. J Clin Virol 32 24-28.
410. P Bonanni, A Franzin, C Staderini, et al. (2005) Vaccination against hepatitis A during outbreaks starting in schools: what can we learn from experiences in central Italy? Vaccine 23 2176-2180.
411. MI Meltzer, CN Shapiro, EE Mast, et al. (2001) The economics of vaccinating restaurant workers against hepatitis A. Vaccine 19 2138-2145.
412. JN Hanna, SL Hills and JL Humphreys (2004) Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in Queensland. MJA 181 482-485.
413. LR Bulkow, RB Wainwright, BJ McMahon, et al. (1993) Secular trends in hepatitis A virus infection among Alaska Natives. J Infect Dis 168 1017-1020.
414. CT Leach, FC Koo, SG Hilsenbeck, et al. (1999) The epidemiology of viral hepatitis in children in South Texas: increased prevalence of hepatitis A along the Texas-Mexico border. J Infect Dis 180 509-513.
415. JJ Amon, N Darling, AE Fiore, BP Bell and LE Barker (2006) Factors associated with hepatitis A vaccination among children 24–35 months of age: United States, 2003. Pediatrics 117 30-33.
416. A Wasley, L Finelli and B Bell (2005) Hepatitis A among U.S. children in era of vaccination. [Abstract 1025]. 43rd Annual Meeting of the Infectious Diseases Society of America, October 6–9, 2005, San Francisco, California Alexandria, VA: Infectious Diseases Society of America
417. Vogt TM, Wise ME, Bell BP, Finelli L. Trends in hepatitis A mortality in the United States 1983–2003. International Society of Viral Hepatitis and Liver Disease, Paris, FRANCE (July, 2006)
418. PL Lopalco, L Salleras, S Barbuti, et al. (2001) Hepatitis A and B in children and adolescents-what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 19 470-474.
419. RJ Jacobs, HS Margolis and PJ Coleman (2000) The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adolesc Med 154 763-770.
420. AS Meyerhoff, RJ Jacobs, HS Margolis, et al. (2000) Cost effectiveness of childhood hepatitis A vaccination in the USA. Antiviral Ther 5(Suppl 1), 10.
421. DB Rein, KA Hicks, KE Wirth, et al. (2007) The cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics 1 e12-e21.
422. GL Armstrong, K Billah, DB Rein, et al. (2007) The economics of routine hepatitis A immunization in the United States: The impact of herd immunity. Pediatrics 1 e22-e29.
423. MJ Postma, JM Bos, P Beutels, et al. (2004) Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Vaccine 22 1862-1867.
424. D Fitzsimons, G Francois, K Alpers, et al. (2005) Prevention of viral hepatitis in the Nordic countries and Germany. Scand J Infect Dis 37(8), 549-560.
425. GJB Sonder, LPMJ Bovée, TD Baayen, et al. (2006) Effectiveness of a hepatitis A vaccination program for migrant children in Amsterdam, The Netherlands (1992–2004). Vaccine 24 4962-4968.
426. Ministerio de Salud y Ambiente de la Nación Calendario nacional de vacunación de la Repóblica Argentina (2006) Retrieved August 4, 2006 from. www.msal.gov.ar/htm/site/vacuna._cal2.asp
427. MA Almuneef, ZA Memish, H Balkhy, et al. (2006) Epidemiologic shift in the prevalence of hepatitis A virus in Saudi Arabia: a case for routine hepatitis A vaccination. Vaccine 24 5599-5603.
428. MT Valenzuela, RJ Jacobs, O Arteaga, et al. (2005) Cost-effectiveness of universal hepatitis A vaccination in Chile. Vaccine 23 4110-4119.
429. A Teppakdee, A Tangwitoon, D Khemasuwan, et al. (2002) Cost-benefit analysis of hepatitis A vaccination in Thailand. Southeast Asian J Trop Med Public Health 33 118-127.
430. DB Rein, AE Fiore and BP Bell (2006) What's next for hepatitis A vaccination? Lancet 367 546-548.
431. Goodman RA, Foster KL, Trowbridge FL, et al. Global disease elimination and eradication as public health strategies. Proceedings of a conference held in Atlanta, Georgia, USA, 23–25 February, 1998. Bull World Health Organ 76:1–162, 1998.
432. EA Emini, JV Hughes, DS Perlow, et al. (1985) Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 55 836-839.
433. JT Stapleton, V Raina, PL Winokur, et al. (1993) Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles. J Virol 67 1080-1085.
434. PL Winokur, JH McLinden and JT Stapleton (1991) The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles. J Virol 65 5029-5036.
435. E Rosen, JT Stapleton and J McLinden (1993) Synthesis of immunogenic hepatitis A virus particles by recombinant baculoviruses. Vaccine 11 706-712.